Company: Eli Lilly
Job title: Research Advisor
Bomie Han, Ph.D., combines protein mass spectrometry and mathematical biology to provide mechanistic understanding of complex biological systems and deliver innovative solutions to challenging problems in drug discovery efforts. He worked many years in Obesity Drug Hunting Team at Eli Lilly and Co. to lead multiple projects as a lead biologist before transitioning to biological mass spectrometry (MS) team in the core technology function within Lilly to support drug hunting projects in multiple therapeutic areas including oncology, cardiovascular diseases, skeletomuscular
diseases and neurodegenerative diseases. His recent work includes developing MS-based epigenetic platform, in vivo and in vitro chemoproteomics to address off-target activities of drug candidates, and mechanistic elucidation of on- and off-target effects by PROTACs and Molecular Glues for development of targeted protein degradation drugs for cancer and neurodegenerative diseases. He got his Ph.D. from Harvard Medical School in Biological Chemistry and Molecular Pharmacology, and B.S from Seoul National University in Chemistry.
Panel Discussion 1:50 pm
What are the similarities and differences between traditional drug discovery and TPD during the pre-clinical discovery efforts and clinical studies? Knowing what we know now, if you were to build a team and a strategy on TPD discovery and development from scratch, what changes would you make if any? What are the key translational bottlenecks…Read more
day: Day Two